Alnylam Pharmaceuticals, Inc.
ALNYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Alnylam Pharmaceuticals, Inc. (ALNY) is listed under Biotechnology. Valued at $35.71B, ALNY is a large-cap name in its sector. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Market Cap
$35.71B
Beta
0.27
P/E (TTM)
70.95
P/E (Fwd)
19.96
EPS (TTM)
$3.77
EPS (Fwd)
$13.40
ROE
90.4%
ROA
10.1%
Cash
$3.01B
Total Debt
$2.97B
Free CF
$204.7M
52W Change
-16.6%
Annual Financials
Cash vs Debt
With $3.01B in cash and $2.97B in debt, ALNY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $204.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 90.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.1% further supports the picture of efficient asset utilization. Revenue has grown from $1.04B (2022) to $3.71B (2025), reflecting a 258% increase over the period.
The relatively low beta of 0.27 suggests ALNY is a less volatile holding compared to the broader index. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ALNY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.